Why the study?
Should molecular screening be performed in family members of genotyped LQTS patients to identify silent gene carriers?
Should molecular screening be performed in family members of genotyped LQTS patients to identify silent gene carriers?
Clinical evaluation alone is insufficient to exclude LQTS in family members of affected patients; molecular screening is recommended to identify silent gene carriers.
No takes yet. Share an insight, caveat, or question.
Clinical evaluation alone may miss silent LQTS carriers at risk; leaves open whether routine molecular screening improves family outcomes.
Priori et al. (1999) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: